Global X China Semiconductor ETF(03191.HK) Rose 5.97% to 92.720
Newtimespace News, as of 15:37 on May 20, Global X China Semiconductor ETF(03191.HK) was quoted at HKD 92.720, up 5.97%. The ETF opened at HKD 87.500, with a high of HKD 92.740 and a low of HKD 87.480. The latest Net Asset Value (NAV) per unit is HKD 87.361, with a premium rate of 0.16%. The asset size is approximately HKD 2.652 billion.
Global X China Semiconductor ETF(03191.HK) tracks the FactSet China Semiconductors Index, which is compiled and published by the global financial data provider FactSet. The index is a net total return index designed to comprehensively reflect the overall performance of companies across the entire Chinese semiconductor industry chain. It provides investors with a high-purity tool for concentrated investment in China's semiconductor industry.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- VSING (08292.HK): Proposes Acquisition of Equity Interest in Golfzon Hong Kong to Build "Technology + Sports + Social" Entertainment Experience
- HK SH ALLIANCE (01001.HK): Subsidiary Unsuccessful in Tender for Tsing Yi Advanced Construction Industry Building Project
- BAIYUNSHAN PH (00874.HK): Dexamethasone Sodium Phosphate Injection (1ml:5mg) of Controlled Subsidiary Passes Generic Consistency Evaluation
- CI FIN TECH GP (08029.HK): Executive Director Wang Qiang Appointed Chairman of the Board; Zheng Meicheng Appointed Vice-chairwoman
- Shaanxi Micot Pharmaceutical Technology Co., Ltd (02335.HK): Phase II Clinical Study of Dual-Function Antithrombotic Candidate MT1002 for Anticoagulation in Haemodialysis Completes First Patient Enrolment